Barrington analyst Michael Petusky raised the firm’s price target on Merit Medical to $100 from $98 and keeps an Outperform rating on the shares. The company reported a strong Q1 beat and its guidance for fiscal 2024 “feels conservative,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI: